文献速递慢性肾脏病水电解质与酸碱血液净化与透析

一项3期、多中心、随机、双盲、安慰剂对照、平行组研究:评估新型静脉钙敏感受体激动剂依特卡肽(ONO-5163/AMG 416)治疗日本血液透析患者继发性甲状旁腺功能亢进的有效性和安全性

A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients.
PubMed 文献 · Nephrol Dial Transplant · 2017-01-01

该3期多中心随机双盲安慰剂对照平行组研究纳入155例血清全段甲状旁腺激素(iPTH)≥300 pg/mL的日本血液透析继发性甲状旁腺功能亢进患者,依特卡肽组78例、安慰剂组77例,依特卡肽每周三次起始5 mg、每4周调整至2.5–15 mg共12周。依特卡肽组达到主要终点(iPTH降至日本透析医学会提出的60–240 pg/mL目标范围)的比例为59.0%,安慰剂组为1.3%,差异显著;依特卡肽组iPTH较基线下降≥30%的比例为76.9%,安慰剂组为5.2%,差异显著。依特卡肽组血清白蛋白校正钙、磷及全段成纤维细胞生长因子-23水平下降,恶心、呕吐及症状性低钙血症轻微,未观察到与依特卡肽相关的严重不良事件。

要点

  • 依特卡肽组59.0%的患者iPTH降至60–240 pg/mL目标范围,安慰剂组仅1.3%。
  • 依特卡肽组76.9%的患者iPTH较基线下降≥30%,安慰剂组为5.2%。
  • 依特卡肽组白蛋白校正钙、磷及全段成纤维细胞生长因子-23水平下降,恶心、呕吐及症状性低钙血症轻微。

核心结论

  • 本研究证明依特卡肽治疗日本血液透析患者继发性甲状旁腺功能亢进有效且安全。
  • 作者认为,作为唯一可用的静脉钙敏感受体激动剂,依特卡肽可能为血液透析患者的继发性甲状旁腺功能亢进提供新的治疗选择。

研究设计与样本

  • 3期、多中心、随机、双盲、安慰剂对照、平行组研究。
  • 共155例血清iPTH≥300 pg/mL的继发性甲状旁腺功能亢进患者,随机分配至依特卡肽组(n=78)或安慰剂组(n=77)。
  • 依特卡肽每周给药三次,起始剂量5 mg,随后每4周调整至2.5–15 mg,共12周。
  • 主要终点为血清iPTH降至日本透析医学会提出的目标范围(60–240 pg/mL)的患者比例。
  • 主要次要终点为血清iPTH较基线下降≥30%的患者比例。

主要发现

  • 达到主要终点的患者比例依特卡肽组为59.0%,安慰剂组为1.3%,依特卡肽组显著高于安慰剂组。
  • 达到主要次要终点的患者比例依特卡肽组为76.9%,安慰剂组为5.2%,依特卡肽组显著高于安慰剂组。
  • 依特卡肽组血清白蛋白校正钙、磷及全段成纤维细胞生长因子-23水平下降。
  • 依特卡肽组恶心、呕吐及症状性低钙血症轻微。
  • 未观察到与依特卡肽相关的严重不良事件。

关键数值与推荐

  • 主要终点目标范围:血清iPTH 60–240 pg/mL(日本透析医学会提出)。
  • 依特卡肽起始剂量5 mg,每周三次,随后每4周调整至2.5–15 mg,共12周。
  • 主要次要终点:血清iPTH较基线下降≥30%。

临床怎么用

  • 作者认为,作为唯一可用的静脉钙敏感受体激动剂,依特卡肽可能为血液透析患者的继发性甲状旁腺功能亢进提供新的治疗选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Secondary hyperparathyroidism (SHPT) is a major complication associated with chronic kidney disease. We evaluated the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, in Japanese haemodialysis patients with SHPT. METHODS: In this phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study, etelcalcetide was administered three times per week at an initial dose of 5 mg, and subsequently adjusted to doses between 2.5 and 15 mg at 4-week intervals for 12 weeks. A total of 155 SHPT patients with serum intact parathyroid hormone (iPTH) levels ≥300 pg/mL were assigned to receive etelcalcetide (n = 78) or placebo (n = 77). The primary endpoint was the proportion of patients with decreased serum iPTH to the target range proposed by the Japanese Society for Dialysis Therapy (60-240 pg/mL). The major secondary endpoint was the proportion of patients with ≥30% reductions in serum iPTH from baseline. RESULTS: The proportion of patients meeting the primary endpoint was significantly higher for etelcalcetide (59.0%) versus placebo (1.3%). Similarly, the proportion of patients meeting the major secondary endpoint was significantly higher for etelcalcetide (76.9%) versus placebo (5.2%). Serum albumin-corrected calcium, phosphorus and intact fibroblast growth factor-23 levels were decreased in the etelcalcetide group. Nausea, vomiting and symptomatic hypocalcaemia were mild with etelcalcetide. Serious adverse events related to etelcalcetide were not observed. CONCLUSIONS: This study demonstrated the efficacy and safety of etelcalcetide. As the only available intravenous calcium-sensing receptor agonist, etelcalcetide is likely to provide a new treatment option for SHPT in haemodialysis patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Fukagawa M, Yokoyama K, Shigematsu T, et al. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant. 2017. PMID: 28057872. doi:10.1093/ndt/gfw408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。